Dose-response study of spinal hyperbaric ropivacaine for cesarean section

Area of Science:

• Anesthesiology
• Obstetrics
• Pharmacology

Background:

• Spinal hyperbaric ropivacaine offers potentially more reliable anesthesia for cesarean sections compared to plain ropivacaine.
• The precise dose-response relationship for spinal hyperbaric ropivacaine in this context remained undetermined prior to this study.

Purpose of the Study:

• To determine the 50% effective dose (ED50) and 95% effective dose (ED95) of spinal hyperbaric ropivacaine for cesarean section anesthesia.
• To establish a reliable dosage range for spinal hyperbaric ropivacaine in obstetric anesthesia.

Main Methods:

• A double-blind, randomized, dose-response study involving 60 parturients undergoing elective cesarean section.
• Parturients received varying doses of spinal hyperbaric ropivacaine (10.5 mg, 12 mg, 13.5 mg, 15 mg) via combined spinal-epidural anesthesia.
• Effectiveness was defined as achieving a T7 sensory level without requiring intraoperative epidural supplementation; logistic regression modeled ED50 and ED95.

Main Results:

• The determined ED50 was 10.37 mg (95% CI: 5.23–11.59 mg) and the ED95 was 15.39 mg (95% CI: 13.81–23.59 mg).
• Higher ropivacaine doses correlated significantly with increased maximum sensory block levels, longer motor block duration, and a higher incidence of hypotension.
• The onset of anesthesia was not significantly related to the dose administered.

Conclusions:

• The ED50 and ED95 for spinal hyperbaric ropivacaine in cesarean delivery were established at 10.37 mg and 15.39 mg, respectively.
• Spinal hyperbaric ropivacaine is confirmed as a suitable agent for spinal anesthesia in cesarean delivery procedures.